TimesSquare Capital Management LLC Invests $30.75 Million in Vaxcyte, Inc. (NASDAQ:PCVX)

TimesSquare Capital Management LLC purchased a new position in Vaxcyte, Inc. (NASDAQ:PCVX) in the 3rd quarter, Holdings Channel reports. The firm purchased 269,121 shares of the company’s stock, valued at approximately $30,752,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. SG Americas Securities LLC bought a new position in shares of Vaxcyte during the 1st quarter valued at approximately $298,000. ClariVest Asset Management LLC purchased a new stake in Vaxcyte in the 1st quarter worth about $283,000. Swiss National Bank lifted its stake in shares of Vaxcyte by 20.4% during the 1st quarter. Swiss National Bank now owns 178,000 shares of the company’s stock worth $12,159,000 after acquiring an additional 30,100 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Vaxcyte during the first quarter valued at $1,288,000. Finally, ProShare Advisors LLC boosted its holdings in shares of Vaxcyte by 23.4% in the first quarter. ProShare Advisors LLC now owns 26,667 shares of the company’s stock valued at $1,822,000 after purchasing an additional 5,060 shares during the period. 96.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on PCVX. Bank of America increased their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Needham & Company LLC reissued a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday. Leerink Partners upped their target price on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday. Finally, Mizuho raised their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte presently has a consensus rating of “Buy” and an average price target of $147.50.

Insider Buying and Selling

In other Vaxcyte news, CEO Grant Pickering sold 2,366 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total value of $245,803.74. Following the completion of the sale, the chief executive officer now directly owns 137,398 shares in the company, valued at $14,274,278.22. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Vaxcyte news, CEO Grant Pickering sold 2,366 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the transaction, the chief executive officer now owns 137,398 shares of the company’s stock, valued at $14,274,278.22. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Elvia Cowan sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the sale, the senior vice president now directly owns 12,723 shares in the company, valued at approximately $1,369,885.41. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 117,464 shares of company stock worth $12,640,276. 3.10% of the stock is owned by insiders.

Vaxcyte Price Performance

Shares of PCVX stock opened at $106.67 on Friday. The stock has a 50 day simple moving average of $111.56 and a 200-day simple moving average of $87.42. Vaxcyte, Inc. has a 1-year low of $46.16 and a 1-year high of $121.06. The company has a market cap of $13.30 billion, a price-to-earnings ratio of -23.19 and a beta of 1.01.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the business earned ($0.91) EPS. Analysts anticipate that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.